Detalle Publicación

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

Autores: Martin, Miguel; Gonzalez-Rivera, Milagros; Morales, Serafin; de la Haba-Rodriguez, Juan; Gonzalez-Cortijo, Lucia; Manso, Luis; Albanell, Joan; González Martín, Antonio; Gonzalez, Sonia; Arcusa, Angels; de la Cruz-Merino, Luis; Rojo, Federico; Vidal, Maria; Galvan, Patricia; Aguirre, Elena; Morales, Cristina; Ferree, Sean; Pompilio, Kristen; Casas, Maribel; Caballero, Rosalia; Goicoechea, Uxue; Carrasco, Eva; Michalopoulos, Steven; Hornberger, John; Prat, Aleix
Título de la revista: CURRENT MEDICAL RESEARCH AND OPINION
ISSN: 1473-4877
Volumen: 31
Número: 6
Páginas: 1129-1137
Fecha de publicación: 2015
Resumen:
Though this study does not include evaluation of the impact of GEP on long-term outcomes, it was found that GEP results influenced the treatment decisions of medical oncologists and their confidence in adjuvant therapy selection. Patients' anxiety about the selected adjuvant therapy decreased with use of the GEP.
DOI: https://doi.org/10.1185/03007995.2015.103773
Impacto:
Google Scholar